Scott Clayton

Scott is an associate editor at TSI Network. He is the lead reporter and analyst for Dividend Advisor, Power Growth Investor and Canadian Wealth Advisor and a member of the Investment Planning Committee. Scott began his investment and financial career working with Pat McKeough at The Investment Reporter in the 1980s. Subsequently, he worked at the Financial Post Corporation Service for 10 years. He joined TSI Network in 1998. He is a Bachelor of Economics graduate of York University, and he also has an M.B.A. from the Schulich School of Business.

Posts by the author
The high rewards of aggressive growth stocks come with high risks
Savvy value stock investors know that many offer dividends with high yields, but not all such dividends are secure.
Even the best junior mining stocks are risky—so it’s important to take steps to minimize that risk
These portfolio risk management techniques will help you build a balanced portfolio and increase your long-term gains
When finding dividend stocks, look at these key factors
Having a sound ETF strategy will help you target the best ETFs—and maximize your gains
Cenovus Energy increased its production at the time of the Alberta wildfires and strategic cost-cutting should save it $500 million in 2016.
WAL-MART STORES INC. $67 (New York symbol WMT; Conservative Growth Dividend Payer Portfolio, Consumer sector; Shares outstanding: 3.1 billion; Market cap: $207.7 billion; Dividend yield: 3.0%; Dividend Sustainability Rating: Highest; www.walmart.com) is the world’s biggest retailer, with 11,633 outlets in 28 countries....
For our December issue of TSI Dividend Advisor we reported on Pfizer’s research spending and recent acquisitions. They will contribute significantly to its future growth.

PFIZER INC. $31 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares o/s: 6.1 billion; Market cap: $189.1 billion; Price-to-sales ratio: 3.6; Dividend Sustainability Rating: Highest; Dividend yield: 3.9%; www.pfizer.com) is one of the world’s leading prescription drugmakers....